Scripps’ phone carrier is experiencing an outage that is affecting some phone lines and faxes. Temporary phone numbers are listed on our Contact Us page. We apologize for any inconvenience and will provide updates as they are available.

Your browser is out-of-date!

Internet Explorer 11 has been retired by Microsoft as of June 15, 2022. To get the best experience on this website, we recommend using a modern browser, such as Safari, Chrome or Edge.

×

Combined Immunotherapy and Radiation Therapy for Non-Small Cell Lung Cancer

Trial ID:
IRB-21-7750
Michael P. Kosty, M.D.
This study will test the effectiveness of Durvalumab (IMFINZI) given during and after radiation treatment in patients with non-small cell lung cancer. Durvalumab is used as an immune-enhancing medication, that may block immune pathways for tumor growth.

Inclusion Criteria

Patients must:
  • Be 18 years of age or older
  • Have confirmed diagnosis of Non-small cell lung cancer (NSCLC), Clinical Stage I/II lymph-node negative (T1 to T3N0M0)
  • Be medically inoperable as determined by your physician or patient refusal of surgery
  • Plan to receive stereotactic body radiation therapy (SBRT)

Exclusion Criteria

Patients must not:
  • Have active or prior autoimmune or inflammatory disorders
  • Have history of another primary cancer
  • Have history of organ transplantation
  • Have active infection of Tuberculosis, Hepatitis B, Hepatitis C or HIV

Additional Info

  • All patients will receive standard of care stereotactic body radiation therapy (SBRT), and will be randomly selected to receive either Durvalumab or placebo via intravenous (IV) infusion. Study treatment and physician visits will take place at Scripps Clinic Torrey Pines (Geisel Pavilion) and occur once monthly for up to two years.
  • Search for NCT03833154 on www.clinicaltrials.gov for additional information.

Contact Info:

  • Clinical Research Services
  • CRSLeadership@scrippshealth.org